Navigation Links
Muscular in Biological Technology

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

... (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, ... the Company intends to apply for a grant from the muscular Dystrophy Association ("MDA") to facilitate an ... RBC Capital Markets." About Myotonic muscular Dystrophy ...

PTC Therapeutics Receives $2.6 Million in Government Grants

... in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). (Logo: ... FDA's Office of Orphan Products Development, the muscular Dystrophy Association, the Parent Project muscular Dystrophy, and the National Center for Research ...

PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration

... advance novel platform for treatment of Spinal muscular Atrophy SOUTH PLAINFIELD, N.J. and NEW ... -- PTC Therapeutics, Inc. (PTC) and the Spinal muscular Atrophy (SMA) Foundation today announced the ... site at www.ptcbio.com . About Spinal muscular Atrophy ...

Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)

... drug discovery and development efforts for spinal muscular atrophy (SMA), the leading genetic cause ... the spinal cord, the disease leads to increasing muscular weakness and atrophy. It is estimated that ... sit up and breathe. Founded in 2003, the Spinal muscular Atrophy Foundation is a nonprofit organization ...

Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program

... "We are very pleased to receive support from the muscular Dystrophy Association, the Friedreich's Ataxia ... Huntington's disease and spinal muscular atrophy. The MDA grant will partially support the ... or cure for Friedreich's ataxia. About the muscular Dystrophy Association ...

PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet

... of PTC124 for nonsense-mutation Duchenne/Becker muscular dystrophy ongoing and are planning ... has also been supported by grants from, the muscular Dystrophy Association, Parent Project muscular Dystrophy, FDA's Office of Orphan Products ...

Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases

... and in nonsense-mutation-mediated Duchenne muscular dystrophy, PTC124 has demonstrated the ability to ... Muscular Dystrophy Association, Parent Project muscular Dystrophy, FDA's Office of Orphan Products ... Center for Research Resources. About Duchenne muscular Dystrophy ...

Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June

... muscular Skeletal Managed Care Organization Takes ... SENECA, N.Y., June 11 /PRNewswire/ -- Palladian muscular Skeletal Health (formerly Prism Health Networks) ... Palladian as the imminent leader in innovative muscular skeletal healthcare solutions," said Paul ...

PTC124 Featured at Third Annual Congress of Myology

... Francaise contre les Myopathies (French muscular Dystrophy Association) and focuses on research, therapies and clinical trials for various forms of muscular dystrophy. (Logo: ... ) PTC124 is being studied in Duchenne muscular dystrophy (DMD), a progressive muscle disorder in ...

AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity

... technology developed for treating Duchenne muscular Dystrophy (DMD) by Robert Kotin, Ph.D., and ... is also important for treatment of Duchenne muscular Dystrophy (DMD) for which AMT has just closed an ... local) expression of therapeutic genes. Duchenne muscular Dystrophy is such a disease, and together with La ...

AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy

... single administration of the product. Duchenne muscular Dystrophy Duchenne muscular dystrophy, caused by mutations in the dystrophin ... will result in long-term treatment of Duchenne muscular dystrophy. Formalizing relationship with ...

Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy

... 19 /PRNewswire-USNewswire/ -- Families of Spinal muscular Atrophy (FSMA); a stem cell scientist at ... Lateral Sclerosis (ALS) in addition to Spinal muscular Atrophy. About Families of Spinal muscular Atrophy: Families of SMA is dedicated to ...

Insmed Awarded $2.1 Million by Muscular Dystrophy Association

... has been awarded a grant of $2,087,325 from the muscular Dystrophy Association (MDA). The grant is ... 3 enabling trial in patients with Myotonic muscular Dystrophy (MMD). Insmed, a development stage ... symptoms commonly associated with Myotonic muscular Dystrophy. Furthermore, patients undergoing a ...

European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera

... SNT-MC17's second potential indication, Duchenne muscular Dystrophy (DMD). About Friedreich's Ataxia ... treatment of Friedreich's Ataxia (FRDA), Duchenne muscular Dystrophy (DMD) and Leber's Hereditary Optic ... comprises SNT-317 (INN: omigapil) in Congenital muscular Dystrophies (CMD), a compound in-licensed ...

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

... Completed the Phase 2 trial of IPLEX(TM) in Myotonic muscular Dystrophy (MMD), and expect preliminary data in the second quarter of ... patients with ALS in Italy and the grant receipt of $1.0 million from the muscular Dystrophy Association supporting the IPLEX(TM) MMD trial. This was ...

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

... patients with ALS in Italy and the grant receipt of $1.0 million from the muscular Dystrophy Association supporting the IPLEX(TM) Phase 2 Myotonic muscular Dystrophy ("MMD") trial. The net loss for the third quarter of 2008 was ...

Insmed CEO to Present at Drug Discovery & Development Conference

... Discuss Company's IPLEX(TM) Program in Myotonic muscular Dystrophy RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. ... Insmed's progress with its Phase II trial for IPLEX(TM) in Myotonic muscular Dystrophy. The trial, which has seen strong patient and physician ...

A New President at the Head of the Genethon Laboratory

... a new president to head the laboratory created in 1990 by the AFM (French muscular Dystrophy Association). Thus Yves Champey succeeds Bernard Barataud, who ... exist with public research organisations." President of the AFM (French muscular Dystrophy Association) from 1981 to 2001, Bernard Barataud is the father ...

Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results

... study of IPLEX(TM) in six patients with myotonic muscular dystrophy ("MMD") that met the primary study endpoints of being ... in 60 patients with MMD; -- Awarded a grant of $2.1 million from the muscular Dystrophy Association ("MDA"), which is expected to cover a ...

PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis

... of PTC124 in nonsense-mutation-mediated cystic fibrosis (CF) and Duchenne muscular dystrophy (DMD). It is estimated that 10% of the cases of CF and 13% of ... European Commission. PTC124's development is supported by grants from the muscular Dystrophy Association (MDA), Cystic Fibrosis Foundation Therapeutics, Inc. ...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

... revenue of $2,588,000, consisting primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) and grant revenue from the muscular Dystrophy Association. Operating expenses for the first quarter of fiscal year 2010 were $6,489,000 compared to $5,702,000 for the same period ...

Muscular protein bond -- strongest yet found in nature

... events from non-specific interactions as well as from multi-molecule events. Their measurements confirm that in the direction that corresponds to muscular contraction and relaxation, the titin-telethonin complex is the strongest protein bond found so far in nature. When force was applied in different ...

iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming

... Highland Capital Partners, MPM Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iPierian has a collaboration ...

Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th

... League Baseball's "4ALS Awareness" campaign. MLB is working with four leading organizations -- The ALS Association, ALS TDI, Augie's Quest (the muscular Dystrophy Association's ALS research initiative) and Project A.L.S. -- whose primary goal is to find a cure for ALS. The initiative will culminate on ...

Ten Top Latin American Scientists Named 2009 Pew Fellows in the Biomedical Sciences

... Eisner, Ph.D. Laboratory of Gyorgy Hajnoczky, M.D., Ph.D. Thomas Jefferson University Mitochondria and muscular disease Ramon A. Jorquera, Ph.D. Laboratory of J. Troy Littleton, M.D., Ph.D. Massachusetts ...

iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board

... extensive knowledge and leadership in neurology to help advance our proprietary neurodegenerative programs in amyotrophic lateral sclerosis, spinal muscular atrophy and Parkinson's disease," said John P. Walker, chief executive officer of iZumi. "Over the next few months, we intend to build a ...

Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results

... $14,833,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) (abatacept) and grant revenue from the muscular Dystrophy Association. Operating expenses for fiscal year 2009 were $25,482,000 compared to $23,574,000, exclusive of the net gain of ...

MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test

... from mutations in mitochondrial DNA is now thought to be common in both adults and children. In childhood, mitochondrial disease is more common than muscular dystrophy or cancer. Most mitochondrial disease may go undiagnosed because a primary care physician does not suspect the disease or because the ...

Insmed Announces First Quarter 2009 Financial Results

... $125 million. IPLEX(TM) Continue to expect preliminary Phase 2 data in Myotonic muscular Dystrophy (MMD) in the second quarter of 2009; The FDA announced that it would allow Insmed to provide access to IPLEX(TM) for ...

iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development

... by Kleiner Perkins Caufield and Byers and Highland Capital Partners. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iZumi has a collaboration with ...

BioMarin Announces First Quarter 2009 Financial Results

... a decision on the future of the 6R-BH4 cardiovascular program by the third quarter of 2009. BMN-195 - Utrophin upregulator for Duchenne muscular Dystrophy: BioMarin is completing reformulation work and toxicology studies and expects to initiate a Phase I trial by the first quarter of 2010. ...

Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research

... "Patients stricken with disabling diseases such as congestive heart failure, diabetes, multiple sclerosis, spinal cord injuries, cerebral palsy, muscular dystrophy, ataxia, autism, COPD, emphysema, Crohn's, and optic nerve disorders, among 100+ other conditions, are receiving successful stem cell ...

Amsterdam Molecular Therapeutics Reports Full Year Results 2008

... resigned for personal reasons - Start of clinical multicenter Hemophilia B trial in 2009 - Start development of treatments for Duchenne muscular Dystrophy and Parkinson's disease - Scale up of unique and proprietary production platform to fully support worldwide commercial ...

Seminar Will Bring ALS Researchers to Patient Groups

... of life issues. The speakers will also describe the impact a three-year, $18 million funding and scientific collaboration between ALS TDI and the muscular Dystrophy Association's Augie's Quest initiative has had on the pace of research, as well as the recently announced 4ALS Awareness charitable ...

Repligen Reports Third Quarter Fiscal Year 2009 Financial Results

... $2,724,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) (abatacept) and grant revenue from the muscular Dystrophy Association. Operating expenses for the third quarter of fiscal year 2009 were $6,556,000 compared to $5,663,000 for the same period ...

Update: Georgia and North Carolina Teens Honored for Research in Biochemistry and Genetics in Nation's Premier High School Science Competition

... with his hypothesis in each case, ultimately creating a shift in the way we think about controlling cell death for diseases such as Parkinson's, muscular Dystrophy and Cancer." Mr. Meixiong is the Team Captain of his school's Science Bowl and the Olympiad Team and also manages his school's swim ...

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants

... further evidence of the effectiveness of IPLEX(TM) in potentially treating some of the most under-served therapeutic populations, including Myotonic muscular Dystrophy and Amyotrophic Lateral Sclerosis." Clinical Study Results Low levels of IGF-I are known to contribute to the pathogenesis of ROP. The ...

Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model

... disease, Repligen is evaluating this family of compounds for activity in preclinical models of other neurodegenerative diseases including spinal muscular atrophy. About The Scripps Research Institute The Scripps Research Institute is one of the world's largest independent, non-profit biomedical ...

Amsterdam Molecular Therapeutics Reports Half Year Results 2008

... for Hyperlipoproteinemia type I - European patent for treatment of Non-Alcoholic Steatotic Hepatitis - License for treatment of Duchenne muscular Dystrophy from La Sapienza University, Rome, Italy - License for prevention of immune response against treatment of Hemophilia B from 'TIGET", San ...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

... financial advisor to evaluate and focus the Company's strategic initiatives. -- IPLEX(TM) -- The Phase 2 trial of IPLEX(TM) in Myotonic muscular Dystrophy ("MMD"), which was initiated in December 2007, has seen a strong patient and physician interest and is now fully enrolled; ...
Other Contents
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
(Date:8/29/2015)... (PRWEB) , ... August 30, 2015 , ... Rio ... O’Shea to serve as the college’s Vice President of Strategic Initiatives and Information Services. ... eager to help the college expand its reach and impact through innovative technologies and ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, ... Applied Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and ... and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
(Date:8/29/2015)... ... , ... Next weekend is Labor Day weekend, the last bash of the ... this year). For IT security personnel, it should also mark the perfect time to ... costly than a simple headache. , Joe Caruso, founder and CEO-CTO of Global ...
(Date:8/29/2015)... New York, NY (PRWEB) , ... August 29, ... ... consistently successful results and include treating the localized area with stretching, soft tissue ... and a neutral pelvic position have shown through research to improve treatment ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
Other TagsOther Tags